02.09.2010 • NewsTotalSanofiGenzyme deal

Total Hopes to Sell Lindsey Refinery by Year-end

French oil company Total has received offers for its UK Lindsey refinery and hopes to sell it by the end of the year, Chief Executive Officer Christophe de Margerie, said on Wednesday.

"We have some offers, we're working on it. We'll talk about it when the moment is right but for the moment the target is that we sell it at the end of the year," de Margerie told journalists on the sidelines of a conference organized by French employers' union Medef.

Referring to the wider market de Margerie said he thought the oil price was "at the right level," while gas prices were low.
"That is a concern for long-term investments but at the same time when you invest today, it is to produce in 8 to 10 years time," he said.

Won't interfere in Sanofi-Genzyme

Total's CEO said he would not comment on the pricing specifics of French pharmaceutical giant Sanofi-Aventis' interest in U.S.-based biotech Genzyme. Total owns a 7.33% stake in Sanofi.

"We are on the board with a relatively small percentage in the share capital. It's up to the management to decide where they want to go and then to ask the board of directors if it is acceptable," de Margerie said.

Genzyme on Monday rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis on Monday, setting the stage for a protracted and potentially hostile takeover battle.

On Tuesday, Genzyme's Chief Executive Henri Termeer said he was willing to sell the company he built up over 25 years, but not for $69 a share.
"I don't think it's good to comment on the price, we will not interfere in the negotiation between two companies," de Margerie said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.